Automating the Review of Aggregate Safety Data - An In-Depth Look

In this Expert Insights webinar presented by MMS Holdings, drug safety and data science professionals will discuss the methods and tools within the pharmacovigilance arena to more efficiently combine data for the purpose of monitoring and signal detection. There is the need for data reviews in real-time and flexibility to visualize this data at both the program and patient level.
The automated review of aggregate data can be implemented to reduce errors and cycle time compared to traditional line listings and static data reviews. Purpose-built tools, like Datacise, which provide visual analytics allowing safety teams to quickly identify potential ADRs and focus on safety signals, will be discussed. Additionally, experts will present an innovative method that saves time and reduces risk by flagging clinically significant events within a subpopulation and across multiple data domains.
Attendees will learn:
-Strategies in the automated review of clinical trial level and aggregate safety data
-Strategies to reduce risk and more efficiently assess safety within your clinical development program
-How purpose-built technologies can reduce errors and reduce review cycle times
Presenters:
Margaryta Mare, MD, Medical Director, Drug Safety & Pharmacovigilance
Aditya Gadiko, MS, Senior Data Scientist
Seun Matthew, MD, MBA, Senior Medical Reviewer
This presentation was originally held on October 29, 2020.